Search results for " colorectal cancer."

showing 10 items of 113 documents

Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany

2013

Risk of colorectal cancer (CRC) is considerably higher in men compared to women; however, there is inconclusive evidence of sex differences in CRC prognosis. We aimed to assess and explain sex differences in 5-year relative survival using standard and model-based period analysis among 164,996 patients diagnosed with CRC from 1997 to 2006 and reported to 11 German cancer registries covering a population of 33 million inhabitants. Age-adjusted 5-year relative survival was higher in women (64.5% vs. 61.9%, P<0.0001). A substantial survival advantage of women was confirmed in multivariate analysis after adjusting for CRC stage and subsite in subjects under 65 years of age (relative excess ri…

MaleOncologyEpidemiologyColorectal cancerlcsh:MedicineSex hormones ; Cancer detection and diagnosis ; Prognosis ; Colorectal cancer ; Rectum ; Colon ; Germany ; Age groups0302 clinical medicineGermanyRegistriesYoung adultlcsh:ScienceAged 80 and overeducation.field_of_studyMultidisciplinaryRelative survivalCancer Risk FactorsColon AdenocarcinomaAge FactorsAbsolute risk reductionMiddle Aged3. Good healthOncologyTransgender hormone therapyPopulation Surveillance030220 oncology & carcinogenesisMedicineFemale030211 gastroenterology & hepatologyColorectal NeoplasmsCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentClinical Research DesignPopulationRectal CancerYoung Adult03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansMortalityeducationBiologyRetrospective StudiesAgedNeoplasm StagingPopulation Biologybusiness.industrylcsh:RCancers and NeoplasmsCancerHormonal Causes of Cancermedicine.diseaseSurgeryLocalized diseaselcsh:QbusinessPLoS ONE
researchProduct

The Insulin Receptor Substrate 1 (Irs1) in Intestinal Epithelial Differentiation and in Colorectal Cancer

2012

Colorectal cancer (CRC) is associated with lifestyle factors that affect insulin/IGF signaling, of which the insulin receptor substrate 1 (IRS1) is a key transducer. We investigated expression, localization and pathologic correlations of IRS1 in cancer-uninvolved colonic epithelium, primary CRCs with paired liver metastases and in vitro polarizing Caco2 and HT29 cells. IRS1 mRNA and protein resulted higher, relative to paired mucosa, in adenomas of familial adenomatous polyposis patients and in CRCs that overexpressed c-MYC, ß-catenin, InsRß, and IGF1R. Analysis of IRS1 immunostaining in 24 cases of primary CRC with paired colonic epithelium and hepatic metastasis showed that staining inten…

MalePathologyAnatomy and PhysiologySettore MED/06 - Oncologia MedicaMetastasisIntestinal mucosaInsulin Signaling CascadeMolecular Cell BiologyGastrointestinal CancersBasic Cancer ResearchInsulinIntestinal MucosaInsulin-like Growth FactorCOLON-CARCINOMA-CELLS; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; FACTOR-I; IGF-I; NUCLEAR TRANSLOCATION; ADENOMATOUS POLYPOSIS; STEM-CELL; EXPRESSION; MUTATIONSMultidisciplinarybiologyChemistryQLiver NeoplasmsRCell PolarityCell DifferentiationSignaling CascadesGene Expression Regulation NeoplasticProtein Transportmedicine.anatomical_structureOncologyMedicineFemaleColorectal NeoplasmsHT29 CellsResearch ArticleSignal TransductionAdultendocrine systemmedicine.medical_specialtyColonScienceIRS1 IGF1R colorectal cancerEndocrine SystemGastroenterology and HepatologySignaling PathwaysFamilial adenomatous polyposisHT29 CellsmedicineHumansBiologyAgedInsulin-like growth factor 1 receptorEndocrine Physiologymedicine.diseasedigestive system diseasesEpitheliumIRS1Insulin receptorInsulin Receptor Substrate Proteinsbiology.proteinCancer researchCaco-2 CellsImmunostainingInsulin-Dependent Signal Transduction
researchProduct

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

2015

// Bruno Vincenzi 1 , Chiara Cremolini 2 , Andrea Sartore-Bianchi 3 , Antonio Russo 4 , Francesco Mannavola 5 , Giuseppe Perrone 6 , Francesco Pantano 1 , Fotios Loupakis 2 , Daniele Rossini 2 , Elena Ongaro 7 , Erica Bonazzina 3 , Emanuela Dell’Aquila 1 , Marco Imperatori 1 , Alice Zoccoli 1 , Giuseppe Bronte 4 , Giovanna De Maglio 7 , Gabriella Fontanini 8 , Clara Natoli 9 , Alfredo Falcone 2 , Daniele Santini 1 , Andrea Onetti-Muda 6 , Salvatore Siena 3 , Giuseppe Tonini 1 and Giuseppe Aprile 7 1 Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy 2 Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy 3 Niguarda Cancer Center, Osped…

MalePathologyColorectal cancerSettore MED/06 - Oncologia MedicaColorectal NeoplasmRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturededucation.field_of_studyUnivariate analysisBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; OncologyLiver NeoplasmsMiddle AgedPrognosisBevacizumabSurvival RateOncologyLiver NeoplasmCohortFemaleK-Ras; mutation rate; colorectal cancer; bevacizumab; prognosisColorectal NeoplasmsK-RasResearch Papermedicine.drugHumanmedicine.medical_specialtyBevacizumabPrognosiMutation ratePopulationBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Rate; Tumor Cells Cultured; OncologyReal-Time Polymerase Chain ReactionFollow-Up StudieProto-Oncogene Proteins p21(ras)Internal medicinemedicineHumanseducationSurvival rateRetrospective StudiesNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerRetrospective cohort studymedicine.diseaseColorectal cancerK-RaMutationbusinessFollow-Up Studies
researchProduct

Chemotherapy of metastatic colon cancer in France: A population-based study

2021

International audience; Aims: to describe, using data from a cancer registry in a well-defined French population, the therapeutic strategies and survival of patients with metastatic colon cancer (mCC).Methods: all patients with synchronous mCC diagnosed within the 2005-2014 period recorded in the digestive cancers registry of Burgundy were included.Results: 1286 mCC patients were included (57% male), of which 34.5% did not receive any antitumor treatment. Both, advanced age (≥75 years) and the Charlson comorbidity score ≥2 were significantly associated with the absence of antitumor treatment. Among the patients treated with chemotherapy, 59 and 33% received at least two and three lines, res…

Malemedicine.medical_specialtyOrganoplatinum Compounds[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinAdenocarcinomaPopulation-basedTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyIn patientRegistrieseducationAgedRetrospective StudiesMetastatic colon cancerChemotherapyeducation.field_of_studyHepatologyMetastatic colorectal cancerbusiness.industryPalliative CareComorbidity scoreAge FactorsGastroenterologyMiddle Aged3. Good healthCancer registry[SDV] Life Sciences [q-bio]Population based study030220 oncology & carcinogenesisColonic NeoplasmsCamptothecinFemale030211 gastroenterology & hepatologyFluorouracilFrancebusiness
researchProduct

Global variation in anastomosis and end colostomy formation following left-sided colorectal resection

2019

Background: End colostomy rates following colorectal resection vary across institutions in high-income settings, being influenced by patient, disease, surgeon and system factors. This study aimed to assess global variation in end colostomy rates after left-sided colorectal resection. Methods: This study comprised an analysis of GlobalSurg-1 and -2 international, prospective, observational cohort studies (2014, 2016), including consecutive adult patients undergoing elective or emergency left-sided colorectal resection within discrete 2-week windows. Countries were grouped into high-, middle- and low-income tertiles according to the United Nations Human Development Index (HDI). Factors associ…

Malemodelos logísticosmedicine.medical_treatmenthumanossurgial careColorectal Neoplasmpaíses desarrolladosLogistic regressionoutcomesGlobal Healthurgencias médicas0302 clinical medicinepaíses en desarrolloSurgicalestudios prospectivosColostomy80 and overglobalsurg030212 general & internal medicineProspective StudiesProspective cohort studyMultivariate Analysimediana edadCancerAged 80 and overEmergencieancianoAnastomosis colorectal resection colostomyAnastomosis SurgicalColostomyGeneral MedicineMiddle Agedadultocolostomy; colorectal cancer; human developlment index3. Good healthColo-Rectal Cancertraditional healersElective Surgical Procedures030220 oncology & carcinogenesisFemaleColorectal Neoplasms6.4 Surgerylow incomeCohort studyHumanDeveloped CountrieAdultAdult; Aged; Aged 80 and over; Anastomosis Surgical; Colorectal Neoplasms; Colostomy; Elective Surgical Procedures; Emergencies; Female; Global Health; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Developed Countries; Developing Countriesmedicine.medical_specialtyneoplasias colorrectalesLogistic Modelcancer anastomosis surgical income stomas colostomy procedure colorectal resection end colostomy emergency surgical procedure human development indexdelayAnastomosishuman developlment indexPerforation (oil well)lcsh:Surgerycolorectal cancerAnastomosisGlobalSurg CollaborativeNO03 medical and health sciencesCase mix indexClinical ResearchmedicinecancerHumansanálisis multifactorialDeveloping CountriesAgedemergency abdominal surgery low income surgial care traditional healers cancer mortality outcomes delayElective Surgical Procedurebusiness.industryKirurgiDeveloped Countriesleft colon resection anastomosis end colostomyEvaluation of treatments and therapeutic interventionslcsh:RD1-811Odds ratiomortalitySurgeryProspective StudieLogistic ModelsMultivariate AnalysisSurgeryEmergenciesbusinessDigestive Diseasescolostomíaemergency abdominal surgery
researchProduct

Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of colorectal cance…

2009

CONTEXT: Computed tomographic (CT) colonography has been recognized as an alternative for colorectal cancer (CRC) screening in average-risk individuals, but less information is available on its performance in individuals at increased risk of CRC. OBJECTIVE: To assess the accuracy of CT colonography in detecting advanced colorectal neoplasia in asymptomatic individuals at increased risk of CRC using unblinded colonoscopy as the reference standard. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, cross-sectional study. Individuals at increased risk of CRC due to either family history of advanced neoplasia in first-degree relatives, personal history of colorectal adenomas, or positiv…

Maleoccult blood testColorectal cancerColonoscopycancer riskprediction and forecastingGastroenterologyRisk Factorscancer diagnosisPositive predicative valueadvanced cancerMedicineFamily historycomparative studycolorectal adenomafamily historyeducation.field_of_studymedicine.diagnostic_testarticleclinical trialGeneral MedicineColonoscopyMiddle Agedpriority journalrisk factorPredictive value of testsdiagnostic accuracyFemalediagnostic valueColorectal NeoplasmsColonography Computed TomographicradiographyComputed TomographicAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAPopulationcolorectal cancerSensitivity and SpecificityPredictive Value of TestsInternal medicineadult; advanced cancer; aged; article; cancer classification; cancer diagnosis; cancer risk; clinical trial; colonoscopy; colorectal adenoma; colorectal cancer; computed tomographic colonography; controlled clinical trial; controlled study; cross-sectional study; diagnostic accuracy; diagnostic value; family history; female; human; major clinical study; male; multicenter study; occult blood test; predictive validity; priority journal; colorectal tumor; comparative study; middle aged; prediction and forecasting; radiography; risk factor; sensitivity and specificity; Adult; Aged; Colonography Computed Tomographic; Colonoscopy; Colorectal Neoplasms; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Risk Factors; Sensitivity and Specificitycross-sectional studyHumanscontrolled studyhumaneducationAgedcontrolled clinical trialbusiness.industryFecal occult bloodSigmoidoscopyColonographymedicine.diseasecancer classificationcomputed tomographic colonographymajor clinical studypredictive validitymulticenter studyCross-Sectional StudiesCT colonography colorectal cancer screeningSettore MED/36 - Diagnostica Per Immagini E Radioterapiabusinesscolorectal tumorJAMA
researchProduct

POSSIBLE RELATION BETWEEN GUT MICROFLORA COMPOSITION AND ONCOGENIC RISK: IS STIMULATION OF INFLAMMATION THE ONE RING OF CONNECTION?

2012

Human intestinalmicrobiotais characterizedby highpopulationdensity, wide diversity and complexity of interactions. Dysbiosis, both qualitative and quantitative, might have serious health consequences including an increase in the number and/or alteration of bacteria colonizing the gastrointestinal tract, which could be referred as gut microflora imbalance (GMI). GMI is frequently found in patients suffering from irritable bowel syndrome; this is the reason why some authors believe that IBS is secondary to GMI. Interestingly, GMI is also found in about 25% of Crohn’s disease patients. Stimulation of inflammation by the ‘dangerous bacteria’, through specific activation of the intestinal immune…

Microbiology (medical)Gastrointestinal tractSettore MED/09 - Medicina InternaInflammationStimulationDiseaseBiologymedicine.diseaseCHRONIC INFLAMMATORY INTESTINAL DISEASES COLORECTAL CANCER COMMENSAL BACTERIA METABOLISM GUT MICROFLORA INTESTINAL STEM CELLS.Settore MED/18 - Chirurgia GeneraleImmune systemImmunologymedicinemedicine.symptomStem cellDysbiosisIrritable bowel syndrome
researchProduct

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta…

2019

Background: Tissue evaluation for RAS (KRAS or NRAS) gene status in metastatic colorectal cancer (mCRC) patients represent the standard of care to establish the optimal therapeutic strategy. Unfortunately, tissue biopsy is hampered by several critical limitations due to its invasiveness, difficulty to access to disease site, patient’s compliance and, more recently, neoplastic tissue spatial and temporal heterogeneity. Methods: The authors performed a systematic literature review to identify available trials with paired matched tissue and ctDNA RAS gene status evaluation. The authors searched EMBASE, MEDLINE, Cochrane, www.ClinicalTrials.gov , and abstracts from international meetings. In to…

Neuroblastoma RAS viral oncogene homologOncologymedicine.medical_specialtyStandard of careColorectal cancerSettore MED/06 - Oncologia Medicamedicine.disease_causelcsh:RC254-282meta-analysi03 medical and health sciences0302 clinical medicineInternal medicinemedicineLiquid biopsy030304 developmental biologyTherapeutic strategycirculating tumor DNAcirculating tumor DNA; diagnostic accuracy; liquid biopsy; meta-analysis; metastatic colorectal cancer; RAS0303 health sciencesliquid biopsybusiness.industrymetastatic colorectal cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthmeta-analysisOncologyCirculating tumor DNA030220 oncology & carcinogenesisMeta-analysisdiagnostic accuracyKRASbusinessRAS
researchProduct

TRIPLET SCHEDULE OF WEEKLY 5-FLUOROURACIL AND ALTERNATING IRINOTECAN OR OXALIPLATIN IN ADVANCED COLORECTAL CANCER: A DOSE-FINDING AND PHASE II STUDY.

2010

A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose- finding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsMaximum Tolerated DoseOrganoplatinum CompoundsSettore MED/06 - Oncologia Medica5-FluorouracilPhases of clinical researchIrinotecanGastroenterologyInternal medicineCPT-11Antineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdvanced colorectal cancerAgedDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseOxaliplatinIrinotecanOxaliplatinSurvival RateRegimenTreatment OutcomeOncologyTolerabilityFluorouracilLymphatic MetastasisToxicityl-OHPCamptothecinFemaleFluorouracilbusinessColorectal NeoplasmsFebrile neutropeniamedicine.drug
researchProduct

“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic …

2009

e15067 Background: The IRIFAFU regimen produced in MCRC pts a consistent activity (RR, 33% [95% CI, 27–39%], PFS, 7.4 [95% CI, 6.5–8.3] mo.) in 2 consecutive randomized SICOG trials . Bev was proven to significantly improve the efficacy of IFL regimen. Here we report the safety and activity results of the BIFF regimen as first-line treatment of MCRC. Patients: From Feb 2007 to Jul 2008, 95 pts with MCRC were treated: so far, 85 pts were evaluated for safety: M/F were 47/38, median age (range) was 64 (35–78) yrs. Fifty-six pts had a colon, and 29 pts a rectal carcinoma. ECOG PS was 0 (63 pts, 74%), or 1 (22 pts, 26%). Thirty-four (40%) pts had 1 site, 33 (39%) 2 sites, and 18 (21%) pts ≥3 s…

OncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerbusiness.industrySettore MED/06 - Oncologia Medicamedicine.diseaseIrinotecanFirst line treatmentRegimenFolinic acidOncologyFluorouracilInternal medicinemedicinebevacizumab metastatic colorectal cancerbusinessmedicine.drug
researchProduct